levofloxacin

Overview

Levofloxacin is a broad-spectrum fluoroquinolone antibiotic used in therapy for susceptible bacterial infections. As the active levo isomer of ofloxacin, it inhibits bacterial DNA gyrase and topoisomerase IV, thereby blocking DNA replication and transcription and leading to bactericidal activity. Clinically, it is valued for its activity against a range of Gram-negative and some Gram-positive organisms, and it is used in both systemic and localized formulations depending on the infection site.

In biomedical research, levofloxacin is frequently studied not only as an antimicrobial agent but also as a comparator or component of combination therapies, especially in settings where biofilm-associated infection, ocular disease, or wound infection complicate treatment. Recent studies have explored its delivery in nanostructured lipid carrier systems, hydrogel-based formulations, and combination regimens with agents such as ibuprofen and clove essential oil to improve local efficacy against resistant or biofilm-forming pathogens such as Pseudomonas aeruginosa and Staphylococcus aureus.

Focus of Latest Publications

Recent investigations of levofloxacin have focused on advancing its therapeutic delivery and efficacy across multiple infection contexts. Studies have explored innovative formulation strategies and combination approaches designed to overcome treatment limitations associated with conventional antibiotic delivery, particularly for biofilm-associated infections and ocular surface diseases.

One approach examined levofloxacin within nanostructured lipid carrier (NLC) systems combined with clove essential oil for treating burn wounds infected with Pseudomonas aeruginosa biofilms. This combination demonstrated strong antibiofilm activity in vitro and in vivo, with the nanoparticles successfully infiltrating biofilm matrices and achieving complete bacterial clearance within seven days, accompanied by significant improvements in wound closure and collagen deposition. In a separate context exploring formulation science, levofloxacin was evaluated as a small-molecule nucleation inhibitor to stabilize ciprofloxacin supersaturation during gastric-to-intestinal pH transitions, sustaining approximately 37% of drug concentration and increasing bioavailability 1.65-fold compared to unaided dissolution.

For ocular infections, levofloxacin was investigated in topical formulations targeting bacterial keratitis caused by Staphylococcus aureus. When combined with ibuprofen as an eye drop preparation, the dual-agent therapy significantly reduced expression of inflammatory mediators, matrix metalloproteinases, and corneal angiogenesis while minimizing apoptosis markers, producing superior therapeutic outcomes compared to single-agent treatment. In comparative assessments, levofloxacin eye drops achieved a 77.4% antibacterial efficacy rate against bacterial keratitis, establishing its baseline performance for evaluating novel antimicrobial-immunomodulatory nanocomposites.

These investigations collectively demonstrate levofloxacin's utility both as a direct antimicrobial agent in combination therapies and as a formulation tool for enhancing delivery of related fluoroquinolones, with particular promise in addressing biofilm-related infections and chronic ocular surface diseases.